HRP20020630A2 - Use of fsh for treating infertility - Google Patents
Use of fsh for treating infertility Download PDFInfo
- Publication number
- HRP20020630A2 HRP20020630A2 HRP20020630A HRP20020630A2 HR P20020630 A2 HRP20020630 A2 HR P20020630A2 HR P20020630 A HRP20020630 A HR P20020630A HR P20020630 A2 HRP20020630 A2 HR P20020630A2
- Authority
- HR
- Croatia
- Prior art keywords
- dose
- fsh
- day
- days
- treatment
- Prior art date
Links
- 208000000509 infertility Diseases 0.000 title claims description 12
- 230000036512 infertility Effects 0.000 title claims description 12
- 231100000535 infertility Toxicity 0.000 title claims description 12
- 238000011282 treatment Methods 0.000 claims description 59
- 230000004936 stimulating effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 claims description 4
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 210000000287 oocyte Anatomy 0.000 description 33
- 210000002966 serum Anatomy 0.000 description 26
- 102000006771 Gonadotropins Human genes 0.000 description 24
- 108010086677 Gonadotropins Proteins 0.000 description 24
- 239000002622 gonadotropin Substances 0.000 description 24
- 230000002611 ovarian Effects 0.000 description 24
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 230000000638 stimulation Effects 0.000 description 22
- 238000002604 ultrasonography Methods 0.000 description 22
- 230000002354 daily effect Effects 0.000 description 21
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 21
- 230000016087 ovulation Effects 0.000 description 20
- 230000035935 pregnancy Effects 0.000 description 20
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 18
- 238000011161 development Methods 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 18
- 230000004044 response Effects 0.000 description 17
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 15
- 210000002257 embryonic structure Anatomy 0.000 description 14
- 229960005309 estradiol Drugs 0.000 description 13
- 229930182833 estradiol Natural products 0.000 description 13
- 102000009151 Luteinizing Hormone Human genes 0.000 description 12
- 108010073521 Luteinizing Hormone Proteins 0.000 description 12
- 229940040129 luteinizing hormone Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000009027 insemination Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- 230000008217 follicular development Effects 0.000 description 9
- 208000021267 infertility disease Diseases 0.000 description 9
- 210000001109 blastomere Anatomy 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 239000000186 progesterone Substances 0.000 description 8
- 229960003387 progesterone Drugs 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 7
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 7
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 7
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 7
- 230000000624 ovulatory effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000001850 reproductive effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000004720 fertilization Effects 0.000 description 6
- 108010006578 follitropin alfa Proteins 0.000 description 6
- 229940057854 gonal f Drugs 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000035800 maturation Effects 0.000 description 6
- 241001227713 Chiron Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 229940094892 gonadotropins Drugs 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 230000031864 metaphase Effects 0.000 description 5
- 230000011599 ovarian follicle development Effects 0.000 description 5
- 210000004508 polar body Anatomy 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940046989 clomiphene citrate Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 108010020661 Profasi Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001817 pituitary effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 238000003744 In vitro fertilisation Methods 0.000 description 2
- 208000034702 Multiple pregnancies Diseases 0.000 description 2
- 208000035002 Pregnancy of unknown location Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042573 Superovulation Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940090047 auto-injector Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 231100000502 fertility decrease Toxicity 0.000 description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 229960004338 leuprorelin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000029849 luteinization Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000009612 semen analysis Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 208000002787 Pregnancy Complications Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 238000012943 effectiveness check Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000002474 gonadorelin antagonist Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00300591 | 2000-01-27 | ||
| EP00302840A EP1142582A1 (en) | 2000-04-04 | 2000-04-04 | Use of FSH for treating infertility |
| PCT/GB2001/000065 WO2001054715A1 (en) | 2000-01-27 | 2001-01-09 | Use of fsh for treating infertility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20020630A2 true HRP20020630A2 (en) | 2004-12-31 |
Family
ID=26072975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20020630 HRP20020630A2 (en) | 2000-01-27 | 2002-07-25 | Use of fsh for treating infertility |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7291593B2 (hu) |
| EP (2) | EP1442748A1 (hu) |
| JP (1) | JP5170928B2 (hu) |
| KR (2) | KR100871502B1 (hu) |
| CN (1) | CN1418107A (hu) |
| AR (1) | AR027287A1 (hu) |
| AT (1) | ATE267608T1 (hu) |
| AU (1) | AU783121B2 (hu) |
| BG (1) | BG65915B1 (hu) |
| BR (1) | BR0107881A (hu) |
| CA (1) | CA2397680A1 (hu) |
| CZ (1) | CZ302835B6 (hu) |
| DE (1) | DE60103503T3 (hu) |
| DK (1) | DK1250148T4 (hu) |
| EA (1) | EA004924B1 (hu) |
| EE (1) | EE05444B1 (hu) |
| ES (1) | ES2217113T5 (hu) |
| HR (1) | HRP20020630A2 (hu) |
| HU (1) | HU230833B1 (hu) |
| IL (2) | IL150837A0 (hu) |
| MX (1) | MXPA02007233A (hu) |
| NO (1) | NO324626B1 (hu) |
| PL (1) | PL211113B1 (hu) |
| PT (1) | PT1250148E (hu) |
| RS (1) | RS50805B (hu) |
| SI (1) | SI1250148T2 (hu) |
| SK (1) | SK287717B6 (hu) |
| TR (1) | TR200401810T4 (hu) |
| WO (1) | WO2001054715A1 (hu) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002324183B2 (en) * | 2001-09-12 | 2007-10-25 | Merck Serono Sa | Use of hCG and LH in controlled ovarian hyperstimulation |
| RS21004A (en) * | 2001-09-12 | 2006-12-15 | Aplied Research Systems Ars Holding N.V. | Use of hcg in controlled ovarian hyperstimulation |
| CN100376289C (zh) * | 2001-09-12 | 2008-03-26 | 应用研究系统Ars股份公司 | 人绒毛膜促性腺激素和黄体生成激素在控制性超排卵中的应用 |
| UA88879C2 (en) * | 2003-09-02 | 2009-12-10 | Эплайд Рисерч Системз Эрс Холдинг Н.В. | Fsh glycosylation mutant |
| US7481748B2 (en) * | 2005-09-22 | 2009-01-27 | Kurt Manufacturing Company, Inc. | Locking mechanism for a bicycle trainer |
| WO2008140794A1 (en) * | 2007-05-11 | 2008-11-20 | The Texas A & M University System | Hormone normalization therapy and uses thereof |
| AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
| WO2015089656A1 (en) * | 2013-12-20 | 2015-06-25 | Fertilify Inc. | Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health |
| CA3073624A1 (en) * | 2017-09-01 | 2019-03-07 | Ferring B.V. | Composition for controlled ovarian stimulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725579A (en) * | 1985-02-21 | 1988-02-16 | Serono Laboratories, Inc. | Method of in vitro fertilization by a unique combination of gonadotropins |
-
2001
- 2001-01-09 HU HU0204324A patent/HU230833B1/hu unknown
- 2001-01-09 EP EP04006375A patent/EP1442748A1/en not_active Withdrawn
- 2001-01-09 AT AT01900491T patent/ATE267608T1/de active
- 2001-01-09 JP JP2001554698A patent/JP5170928B2/ja not_active Expired - Lifetime
- 2001-01-09 EP EP01900491A patent/EP1250148B2/en not_active Expired - Lifetime
- 2001-01-09 RS YUP-567/02A patent/RS50805B/sr unknown
- 2001-01-09 EA EA200200801A patent/EA004924B1/ru not_active IP Right Cessation
- 2001-01-09 DE DE60103503T patent/DE60103503T3/de not_active Expired - Lifetime
- 2001-01-09 SI SI200130111T patent/SI1250148T2/sl unknown
- 2001-01-09 DK DK01900491T patent/DK1250148T4/da active
- 2001-01-09 ES ES01900491T patent/ES2217113T5/es not_active Expired - Lifetime
- 2001-01-09 MX MXPA02007233A patent/MXPA02007233A/es active IP Right Grant
- 2001-01-09 AU AU25321/01A patent/AU783121B2/en not_active Expired
- 2001-01-09 CA CA002397680A patent/CA2397680A1/en not_active Abandoned
- 2001-01-09 CN CN01806573A patent/CN1418107A/zh active Pending
- 2001-01-09 TR TR2004/01810T patent/TR200401810T4/xx unknown
- 2001-01-09 CZ CZ20022555A patent/CZ302835B6/cs not_active IP Right Cessation
- 2001-01-09 US US10/182,138 patent/US7291593B2/en not_active Expired - Lifetime
- 2001-01-09 BR BR0107881-0A patent/BR0107881A/pt not_active Application Discontinuation
- 2001-01-09 SK SK1096-2002A patent/SK287717B6/sk not_active IP Right Cessation
- 2001-01-09 PT PT01900491T patent/PT1250148E/pt unknown
- 2001-01-09 IL IL15083701A patent/IL150837A0/xx unknown
- 2001-01-09 WO PCT/GB2001/000065 patent/WO2001054715A1/en active IP Right Grant
- 2001-01-09 KR KR1020027009518A patent/KR100871502B1/ko active IP Right Grant
- 2001-01-09 KR KR1020077017998A patent/KR100871499B1/ko active IP Right Grant
- 2001-01-09 PL PL356925A patent/PL211113B1/pl unknown
- 2001-01-09 EE EEP200200415A patent/EE05444B1/xx unknown
- 2001-01-25 AR ARP010100325A patent/AR027287A1/es unknown
-
2002
- 2002-07-11 NO NO20023354A patent/NO324626B1/no not_active IP Right Cessation
- 2002-07-22 IL IL150837A patent/IL150837A/en active IP Right Grant
- 2002-07-23 BG BG106943A patent/BG65915B1/bg unknown
- 2002-07-25 HR HRP20020630 patent/HRP20020630A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meldrum et al. | Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval | |
| EP1250148B1 (en) | Use of fsh for treating infertility | |
| EP1511537B1 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| JP2003520823A5 (hu) | ||
| JP2023527221A (ja) | 不妊症の処置における使用のためのｈｐ－ｈｍｇを含む組成物 | |
| AU2005203211B2 (en) | Use of FSH for treating infertility | |
| EP1142582A1 (en) | Use of FSH for treating infertility | |
| JP2023534400A (ja) | 多嚢胞性卵巣症候群の患者における不妊症の処置での使用のためのＨＰ－ｈＭＧ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20041206 Year of fee payment: 5 |
|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PPPP | Transfer of rights |
Owner name: LABORATOIRES SERONO SA, CH |
|
| ODBI | Application refused |